GSK’s Arexy and Pfizer’s Abrysvo vaccines for respiratory syncytial virus (RSV) have received recommendations from the US Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP). While the committee voted almost unanimously in support of the vaccines for adults aged 60-64, the recommendation for adults over 65 was far more contentious, sitting at 9-5 for and against, respectively.
According to Kevin Dunleavy, “The primary sticking point for the committee in assessing the value and safety of the vaccines was that the trials conducted by both companies failed to include enough people of advanced age. The committee also was disappointed that both companies failed to reveal the price of their vaccines. When pressed, GSK refined its price range, guaranteeing its shot will be available for between $200 and $295 per dose. Pfizer did not move off its price range entering the meeting of between $180 to $270 per shot.”
To read more, click here.
(Source: Fierce Pharma, June 22nd, 2023)